Peringkat dalam Saham
#11212
EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating... EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.
Harga Saham
$2.34
Terakhir disinkronkan: 2023-11-09
Kapitalisasi Pasar
$728.90M
Perubahan (1 tahun)
0.00%
Perdagangan EQRx, Inc. (EQRX)
Harga EQRX dengan kapitalisasi pasar B
Kapitalisasi pasar dari EQRx, Inc.(EQRX)
Kapitalisasi Pasar: $728.90M
Per August 2026, EQRx, Inc. memiliki kapitalisasi pasar sebesar $728.90M. Ini menjadikan EQRx, Inc. sebagai perusahaan 11212th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar EQRx, Inc. dari 2021 hingga 2026
EQRX dibandingkan dengan 5 teratas stocks paling populer
| Harga EQRX |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.264T
|
+722,063.20%
|
|
|
|
|
$4.701T
|
+644,879.82%
|
|
|
|
|
$4.177T
|
+572,977.48%
|
|
|
|
|
$3.817T
|
+523,618.82%
|
|
|
|
|
$2.866T
|
+393,139.94%
|
